Attachment
PennyOmega.com is pleased to announce its Stock Alert
We encourage investors to join the FREE daily e-mail alerts by visiting:
http://www.PennyOmega.com/
__
PWRM, Power 3 Medical Products Inc., PWRM.OB
PWRM is a leading biotechnology company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases such as Alzheimer’s disease and Parkinson’s disease and amyotrophic lateral sclerosis (commonly known as ALS or Lou Gehrig’s disease).
PWRM applies proprietary methodologies to discover and identify protein biomarkers associated with diseases. Through these processes, Power3 has developed a portfolio of products including BC-SeraPro, a proteomic blood serum test for the early detection of breast cancer for which it has completed Phase I clinical trials, and NuroPro, a serum test for the detection of neurodegenerative diseases, including Alzheimer’s, Parkinson’s and ALS diseases, currently engaged in Phase II clinical trials.
PWRM’s NuroPro was originally indicated for diagnostics to determine whether or not a patient had Alzheimer’s disease.
Recently, PWRM has unexpectedly discovered new and unprecedented findings regarding clinically important differences in the response of the NuroPro protein biomarkers in the blood of untreated Alzheimer’s disease patients compared to patients treated with the widely used anti-dementia drugs Aricept (Donepezil HCl, Pfizer – NYSE: PFE), Exelon (Rivastigmine, Novartis – NYSE: NVS), and Namenda (Memantine HCl, Forest Laboratories – NYSE: FRX). These results relate to the genetically distinct groups of Alzheimer’s disease patients, i.e., those individuals who possess the Alzheimer’s high-risk gene for Apolipoprotein E4 and those who do not possess the gene.
With these results, NuroPro now extends into the pharmaceutical arena due to its ability to predict and monitor the response to drug treatment, including the underlying disease process and the insidious progression of irreversible neurological damage, even in the face of temporary improvements in cognition and other symptoms.
PWRM has filed for patent protection for these findings and will be publishing these seminal results in the near future in one of the world’s most prestigious peer-reviewed scientific journals. Power3 also plans to demonstrate the clinical application and benefits of its NuroPro diagnostic tests to healthcare providers located throughout the world.
************************************************************
NEXM, NexMed, Inc.
NEXM is the largest specialty CRO based in San Diego, CA and is one of the industry's most experienced CROs for in vitro and in vivo pharmacology services and research models.
NEXM, a specialty CRO with a pipeline of products based on the NexACT technology, today announced results from a pre-clinical study showing that calcipotriene 0.005% and betamethasone dipropionate 0.064%, when formulated with NexACT, results in a topical treatment which shows bioequivalecy in efficacy to Talconex, one of the leading topical treatments marketed for patients with mild to moderate psoriasis.
Psoriasis is a chronic autoimmune disease that appears on the skin. It occurs when the immune system sends out faulty signals that speed up the growth cycle of skin cells.
More about NEXM at www.nexmed.com
__
***FREE DAILY STOCK ALERTS**
Sign up to receive FREE stock alerts from PennyOmega.com at http://www.PennyOmega.com/
About PennyOmega.com
PennyOmega.com is a stock watch website, a Crown Equity Holdings, Inc. division that provides free daily alerts on stocks. PennyOmega.com's alerts are daily e-mail on stocks that are hot in the market. These include stocks with huge volume, penny stocks, stocks with technical indicators and much more. PennyOmega.com also tracks small cap stocks that are on the brink of moving upwards. PennyOmega.com also features companies on its website with research report, analysis, and newsletters.
PennyOmega.com is an independent electronic publication that provides information on selected publicly traded companies. PennyOmega.com is not a registered investment advisor or broker-dealer.
PennyOmega.com and Crown Equity Holdings, Inc., affiliates, officers, directors, contractors and employees, including may buy and sell additional shares in any company mentioned herein and may profit in the event those shares rise in value. Please do your own Due Diligence before investing in any of the stocks mentioned above.
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Please do your own Due Diligence before investing in any of the stocks mentioned above. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our sites, stock alerts, watch list or joining our email list. Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (CRWE.OB) has previously received five hundred thousand shares compensation for 30 days of advertisement services and received an additional 1,000,000 shares 144 restricted stocks for a continuation of 6 months of advertisement and disseminating news, as well as $15,000 dollars for IR services for Power 3 Medical Products Inc. (PWRM.OB). Recently, Crown Equity Holdings, Inc has received an additional amount of 2,000,000 shares of free trading stock for 60 days media advertisement, web design and maintenance for Power 3 Medical Products Inc. (PWRM.OB) Full disclaimer can be read at www.PennyOmega.com.
Release of Liability: Through use of our website, Email Alerts, and stock alerts viewing or using, you agree to hold PennyOmega.com, Crown Equity Holdings, Inc., its operators, shareholders, consultants, associates and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data.
PennyOmega.com and Crown Equity Holdings, Inc. affiliates and associates may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. Crown Equity Holdings, Inc. encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and PennyOmega.com makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies.
Forward Looking Statement
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are not guarantees of future performance and involve significant risks and uncertainties. Actual results may vary materially from those in the forward-looking statements as a result of the effectiveness of management's strategies and decisions, general economic and business conditions, new or modified statutory or regulatory requirements and changing price and market conditions. No assurance can be given that these are all the factors that could cause
actual results to vary materially from the forward-looking statements. Therefore, you should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements.
Contact:
PennyOmega.com
E-mail: arnu@PennyOmega.com
Phone: (702) 448-1543
FREE: 1-877-
FAX: (702) 479-7151
Photo:
http://www.prlog.org/
